Vascular endothelial growth factor gene polymorphisms in ovarian cancer.
BACKGROUND
Polymorphisms within the vascular endothelial growth factor (VEGF) gene, the most important regulator of angiogenesis and vascular permeability, were shown to be independently associated with an impaired prognosis in various malignancies. No data have been reported in ovarian cancer.


METHODS
In the present multi-center study, we examined three common polymorphisms within the VEGF gene (VEGF +405G/C, VEGF -460C/T, and VEGF +936C/T) in 553 Caucasian patients with ovarian cancer using pyrosequencing.


RESULTS
The three investigated polymorphisms did not correlate with any of the investigated clinico-pathological parameters. In univariate and multivariate models, only FIGO stage and patient's age at diagnosis, but not any polymorphism or any haplotype were correlated with patients' overall survival.


CONCLUSIONS
In our large multi-center study, the investigated VEGF gene polymorphisms were not associated with prognosis in patients with ovarian cancer.
Polterauer
Stephan
S
Department of Obstetrics and Gynecology, Medical University of Vienna, A-1090 Vienna, Währinger Gürtel 18-20, Austria.
Grimm
Christoph
C
Mustea
Alexander
A
Concin
Nicole
N
Tanner
Berno
B
Thiel
Falk
F
Heinze
Georg
G
Reinthaller
Alexander
A
Zeillinger
Robert
R
Hefler
Lukas A
LA
D000368:Aged; D005260:Female; D005838:Genotype; D006801:Humans; D015810:Linkage Disequilibrium; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000235:genetics; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000235:genetics* / Q000473:pathology; D011110:Polymorphism, Genetic; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
D042461:Vascular Endothelial Growth Factor A